As such, inhibition of Lig4 may prove beneficial in combination with therapeutic application of the FDA-approved breast-specific stereotactic body radiotherapy device GammaPod, which delivers a high (8 Gy), but localized dose of radiation for breast cancer treatment [34]. This evidence concerns the gene LIG4 and breast cancer.